Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity. 2018

Kelsey E Sivick, and Anthony L Desbien, and Laura Hix Glickman, and Gabrielle L Reiner, and Leticia Corrales, and Natalie H Surh, and Thomas E Hudson, and Uyen T Vu, and Brian J Francica, and Tamara Banda, and George E Katibah, and David B Kanne, and Justin J Leong, and Ken Metchette, and Jacob R Bruml, and Chudi O Ndubaku, and Jeffrey M McKenna, and Yan Feng, and Lianxing Zheng, and Steven L Bender, and Charles Y Cho, and Meredith L Leong, and Andrea van Elsas, and Thomas W Dubensky, and Sarah M McWhirter
Aduro Biotech, Inc., Berkeley, CA 94710, USA.

Intratumoral (IT) STING activation results in tumor regression in preclinical models, yet factors dictating the balance between innate and adaptive anti-tumor immunity are unclear. Here, clinical candidate STING agonist ADU-S100 (S100) is used in an IT dosing regimen optimized for adaptive immunity to uncover requirements for a T cell-driven response compatible with checkpoint inhibitors (CPIs). In contrast to high-dose tumor ablative regimens that result in systemic S100 distribution, low-dose immunogenic regimens induce local activation of tumor-specific CD8+ effector T cells that are responsible for durable anti-tumor immunity and can be enhanced with CPIs. Both hematopoietic cell STING expression and signaling through IFNAR are required for tumor-specific T cell activation, and in the context of optimized T cell responses, TNFα is dispensable for tumor control. In a poorly immunogenic model, S100 combined with CPIs generates a survival benefit and durable protection. These results provide fundamental mechanistic insights into STING-induced anti-tumor immunity.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009418 S100 Proteins A family of highly acidic calcium-binding proteins found in large concentration in the brain and believed to be glial in origin. They are also found in other organs in the body. They have in common the EF-hand motif (EF HAND MOTIFS) found on a number of calcium binding proteins. The name of this family derives from the property of being soluble in a 100% saturated ammonium sulfate solution. Antigen S 100,Nerve Tissue Protein S 100,S100 Protein,S-100 Protein,S100 Protein Family,Protein, S100,S 100 Protein
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D006410 Hematopoiesis The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY). Hematopoiesis, Medullary,Haematopoiesis,Medullary Hematopoiesis
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine

Related Publications

Kelsey E Sivick, and Anthony L Desbien, and Laura Hix Glickman, and Gabrielle L Reiner, and Leticia Corrales, and Natalie H Surh, and Thomas E Hudson, and Uyen T Vu, and Brian J Francica, and Tamara Banda, and George E Katibah, and David B Kanne, and Justin J Leong, and Ken Metchette, and Jacob R Bruml, and Chudi O Ndubaku, and Jeffrey M McKenna, and Yan Feng, and Lianxing Zheng, and Steven L Bender, and Charles Y Cho, and Meredith L Leong, and Andrea van Elsas, and Thomas W Dubensky, and Sarah M McWhirter
June 2019, Biomaterials,
Kelsey E Sivick, and Anthony L Desbien, and Laura Hix Glickman, and Gabrielle L Reiner, and Leticia Corrales, and Natalie H Surh, and Thomas E Hudson, and Uyen T Vu, and Brian J Francica, and Tamara Banda, and George E Katibah, and David B Kanne, and Justin J Leong, and Ken Metchette, and Jacob R Bruml, and Chudi O Ndubaku, and Jeffrey M McKenna, and Yan Feng, and Lianxing Zheng, and Steven L Bender, and Charles Y Cho, and Meredith L Leong, and Andrea van Elsas, and Thomas W Dubensky, and Sarah M McWhirter
February 2021, Oncotarget,
Kelsey E Sivick, and Anthony L Desbien, and Laura Hix Glickman, and Gabrielle L Reiner, and Leticia Corrales, and Natalie H Surh, and Thomas E Hudson, and Uyen T Vu, and Brian J Francica, and Tamara Banda, and George E Katibah, and David B Kanne, and Justin J Leong, and Ken Metchette, and Jacob R Bruml, and Chudi O Ndubaku, and Jeffrey M McKenna, and Yan Feng, and Lianxing Zheng, and Steven L Bender, and Charles Y Cho, and Meredith L Leong, and Andrea van Elsas, and Thomas W Dubensky, and Sarah M McWhirter
November 2023, iScience,
Kelsey E Sivick, and Anthony L Desbien, and Laura Hix Glickman, and Gabrielle L Reiner, and Leticia Corrales, and Natalie H Surh, and Thomas E Hudson, and Uyen T Vu, and Brian J Francica, and Tamara Banda, and George E Katibah, and David B Kanne, and Justin J Leong, and Ken Metchette, and Jacob R Bruml, and Chudi O Ndubaku, and Jeffrey M McKenna, and Yan Feng, and Lianxing Zheng, and Steven L Bender, and Charles Y Cho, and Meredith L Leong, and Andrea van Elsas, and Thomas W Dubensky, and Sarah M McWhirter
October 2022, Anti-cancer drugs,
Kelsey E Sivick, and Anthony L Desbien, and Laura Hix Glickman, and Gabrielle L Reiner, and Leticia Corrales, and Natalie H Surh, and Thomas E Hudson, and Uyen T Vu, and Brian J Francica, and Tamara Banda, and George E Katibah, and David B Kanne, and Justin J Leong, and Ken Metchette, and Jacob R Bruml, and Chudi O Ndubaku, and Jeffrey M McKenna, and Yan Feng, and Lianxing Zheng, and Steven L Bender, and Charles Y Cho, and Meredith L Leong, and Andrea van Elsas, and Thomas W Dubensky, and Sarah M McWhirter
March 1990, Journal of immunology (Baltimore, Md. : 1950),
Kelsey E Sivick, and Anthony L Desbien, and Laura Hix Glickman, and Gabrielle L Reiner, and Leticia Corrales, and Natalie H Surh, and Thomas E Hudson, and Uyen T Vu, and Brian J Francica, and Tamara Banda, and George E Katibah, and David B Kanne, and Justin J Leong, and Ken Metchette, and Jacob R Bruml, and Chudi O Ndubaku, and Jeffrey M McKenna, and Yan Feng, and Lianxing Zheng, and Steven L Bender, and Charles Y Cho, and Meredith L Leong, and Andrea van Elsas, and Thomas W Dubensky, and Sarah M McWhirter
January 2020, Frontiers in immunology,
Kelsey E Sivick, and Anthony L Desbien, and Laura Hix Glickman, and Gabrielle L Reiner, and Leticia Corrales, and Natalie H Surh, and Thomas E Hudson, and Uyen T Vu, and Brian J Francica, and Tamara Banda, and George E Katibah, and David B Kanne, and Justin J Leong, and Ken Metchette, and Jacob R Bruml, and Chudi O Ndubaku, and Jeffrey M McKenna, and Yan Feng, and Lianxing Zheng, and Steven L Bender, and Charles Y Cho, and Meredith L Leong, and Andrea van Elsas, and Thomas W Dubensky, and Sarah M McWhirter
September 2022, Journal of translational medicine,
Kelsey E Sivick, and Anthony L Desbien, and Laura Hix Glickman, and Gabrielle L Reiner, and Leticia Corrales, and Natalie H Surh, and Thomas E Hudson, and Uyen T Vu, and Brian J Francica, and Tamara Banda, and George E Katibah, and David B Kanne, and Justin J Leong, and Ken Metchette, and Jacob R Bruml, and Chudi O Ndubaku, and Jeffrey M McKenna, and Yan Feng, and Lianxing Zheng, and Steven L Bender, and Charles Y Cho, and Meredith L Leong, and Andrea van Elsas, and Thomas W Dubensky, and Sarah M McWhirter
January 2023, Immunity,
Kelsey E Sivick, and Anthony L Desbien, and Laura Hix Glickman, and Gabrielle L Reiner, and Leticia Corrales, and Natalie H Surh, and Thomas E Hudson, and Uyen T Vu, and Brian J Francica, and Tamara Banda, and George E Katibah, and David B Kanne, and Justin J Leong, and Ken Metchette, and Jacob R Bruml, and Chudi O Ndubaku, and Jeffrey M McKenna, and Yan Feng, and Lianxing Zheng, and Steven L Bender, and Charles Y Cho, and Meredith L Leong, and Andrea van Elsas, and Thomas W Dubensky, and Sarah M McWhirter
February 1994, The Journal of experimental medicine,
Kelsey E Sivick, and Anthony L Desbien, and Laura Hix Glickman, and Gabrielle L Reiner, and Leticia Corrales, and Natalie H Surh, and Thomas E Hudson, and Uyen T Vu, and Brian J Francica, and Tamara Banda, and George E Katibah, and David B Kanne, and Justin J Leong, and Ken Metchette, and Jacob R Bruml, and Chudi O Ndubaku, and Jeffrey M McKenna, and Yan Feng, and Lianxing Zheng, and Steven L Bender, and Charles Y Cho, and Meredith L Leong, and Andrea van Elsas, and Thomas W Dubensky, and Sarah M McWhirter
May 2024, Cell reports. Medicine,
Copied contents to your clipboard!